Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
28 pending office actions • 10 art units • 23 examiners • 0 of 28 (0%) have an AI response strategy ready • 29 patents granted in the last 365 days
Novo Nordisk A/S has 27 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 22 examiners and 10 art units, indicating meaningful examiner distribution within a more limited set of technical units.
CHANDRA, GYAN is the busiest examiner, with 3 pending matters. Counsel should combine art-unit awareness with matter-specific prosecution planning, while using consistent positions where related biotechnology issues recur.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (4%) |
| §103 only | 6 (21%) |
| §102 only | 1 (4%) |
| §112 only | 3 (11%) |
| Double-patenting only | 2 (7%) |
| Double-patenting + other | 4 (14%) |
| Multi-statute (no §101) | 11 (39%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRA, GYAN | 3 | 71.3% | +27.5% |
| HELLMAN, KRISTINA M | 2 | 65.1% | +55.5% |
| ARCORIA, PAUL JOSEPH | 2 | 100.0% | +0.0% |
| BRADLEY, CHRISTINA | 2 | 62.6% | +33.3% |
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +68.7% |
| TURKOWSKI, KAYLA MARIE | 1 | 67.9% | +50.4% |
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
| KASHYAP, ESHA PRAKASH | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18839945 | METHODS FOR TREATING SUBJECTS WITH ABDOMINAL OBESITY HYPERTRIGLYCERIDEMIA AND/OR IMPAIRED GLUCOSE | ARCORIA, PAUL JOSEPH | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19310993 | SEMAGLUTIDE FOR USE IN MEDICINE | DABKOWSKI, ERINNE R | 31d overdue |
| 18015444 | METHODS FOR TREATING CARDIOVASCULAR DISEASE | HOWARD, ZACHARY C | 26d |
| 19415046 | PEPTIDE ANALOGS AND METHODS OF USING THE SAME | CHANDRA, GYAN | — |
| 18837928 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | ARCORIA, PAUL JOSEPH | — |
| 18681845 | INGESTIBLE DEVICE | KASHYAP, ESHA PRAKASH | — |
| 18578485 | SODIUM N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLATE POLYMORPHIC FORM A | ANTHOPOLOS, PETER | — |
| 18252056 | COMPOUNDS AND THEIR USE IN TREATMENT OF TACHYKININ RECEPTOR MEDIATED DISORDERS | BRADLEY, CHRISTINA | — |
| 17782313 | FIXED DOSE INJECTION DEVICE | FARRAR, LAUREN PENG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19310993 | SEMAGLUTIDE FOR USE IN MEDICINE | DABKOWSKI, ERINNE R | 31d overdue |
| 19463848 | SEMAGLUTIDE IN MEDICAL THERAPY | COFFA, SERGIO | — |
| 19415046 | PEPTIDE ANALOGS AND METHODS OF USING THE SAME | CHANDRA, GYAN | — |
| 19404431 | TRI-AGONISTS OF THE GLP-1, GIP, AND AMYLIN RECEPTORS AND USES THEREOF | HELLMAN, KRISTINA M | — |
| 19378410 | SEMAGLUTIDE IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 18832669 | INGESTIBLE DEVICE WITH DETACHMENT OF TISSUE PENETRATING MEMBER | TURKOWSKI, KAYLA MARIE | — |
| 18723131 | PROCESS FOR THE BACKBONE DEPROTECTION OF OLIGONUCLEOTIDES CONTAINING A TERMINAL ALKYL PHOSPHONATE GROUP | GALSTER, SAMUEL LEONARD | — |
| 18673424 | Combination Therapy for Treatment of Liver Disease | BRADLEY, CHRISTINA | — |
| Art Unit | Apps |
|---|---|
| 3783 | 8 |
| 1654 | 5 |
| 1674 | 4 |
| 1658 | 3 |
| 1621 | 2 |
| 1626 | 2 |
| 1693 | 1 |
| 1641 | 1 |
| 1612 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19463848 | SEMAGLUTIDE IN MEDICAL THERAPY | COFFA, SERGIO | 1658 | DP | Final Rejection | — | Pending | Jan 29, 2026 |
| 19415046 | PEPTIDE ANALOGS AND METHODS OF USING THE SAME | CHANDRA, GYAN | 1674 | §103§112 | Non-Final OA | — | Pending | Dec 10, 2025 |
| 19404431 | TRI-AGONISTS OF THE GLP-1, GIP, AND AMYLIN RECEPTORS AND USES THEREOF | HELLMAN, KRISTINA M | 1654 | §112 | Non-Final OA | — | Pending | Dec 01, 2025 |
| 19378410 | SEMAGLUTIDE IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103§112DP | Non-Final OA | — | Pending | Nov 04, 2025 |
| 19310993 | SEMAGLUTIDE FOR USE IN MEDICINE | DABKOWSKI, ERINNE R | 1654 | §101 | Final Rejection | 31d overdue | Pending | Aug 27, 2025 |
| 18839945 | METHODS FOR TREATING SUBJECTS WITH ABDOMINAL OBESITY HYPERTRIGLYCERIDEMIA AND/OR IMPAIRED GLUCOSE | ARCORIA, PAUL JOSEPH | 1621 | §103 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18837928 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | ARCORIA, PAUL JOSEPH | 1621 | §103§112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18832669 | INGESTIBLE DEVICE WITH DETACHMENT OF TISSUE PENETRATING MEMBER | TURKOWSKI, KAYLA MARIE | 3783 | §112 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18723131 | PROCESS FOR THE BACKBONE DEPROTECTION OF OLIGONUCLEOTIDES CONTAINING A TERMINAL ALKYL PHOSPHONATE GROUP | GALSTER, SAMUEL LEONARD | 1693 | §103 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18673424 | Combination Therapy for Treatment of Liver Disease | BRADLEY, CHRISTINA | 1654 | §103 | Non-Final OA | — | Pending | May 24, 2024 |
| 18591754 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | CHANDRA, GYAN | 1674 | §112DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18681845 | INGESTIBLE DEVICE | KASHYAP, ESHA PRAKASH | 3783 | §102§103 | Final Rejection | — | Pending | Feb 06, 2024 |
| 18426412 | GLP-1 RECEPTOR AGONISTS IN DEMENTIA | CHANDRA, GYAN | 1674 | §102§103DP | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18578485 | SODIUM N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLATE POLYMORPHIC FORM A | ANTHOPOLOS, PETER | 1626 | §102§103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18242868 | FACTOR X BINDERS ENHANCING FX ACTIVATION | SZPERKA, MICHAEL EDWARD | 1641 | §112DP | Final Rejection | 5d overdue | Pending | Sep 06, 2023 |
| 18271985 | A TORSION SPRING DRIVEN FIXED DOSE INJECTION DEVICE | MEDWAY, SCOTT J | 3783 | §102 | Final Rejection | — | Pending | Jul 12, 2023 |
| 18252056 | COMPOUNDS AND THEIR USE IN TREATMENT OF TACHYKININ RECEPTOR MEDIATED DISORDERS | BRADLEY, CHRISTINA | 1654 | §103§112 | Non-Final OA | — | Pending | May 08, 2023 |
| 18020386 | INGESTIBLE DRUG DELIVERY DEVICE | GONZALEZ, LEI NMN | 3783 | §103 | Non-Final OA | 26d | Pending | Feb 08, 2023 |
| 18015444 | METHODS FOR TREATING CARDIOVASCULAR DISEASE | HOWARD, ZACHARY C | 1674 | §103§112 | Non-Final OA | 26d | Pending | Jan 10, 2023 |
| 17913292 | Solid Dispersions of Amorphous 3,4-Diphenyl-4,5-Dihydro-1H-Pyrazole Derivatives, Compositions Comprising them and Uses Thereof as Cannabinoid CB1 Receptor Inhibitors | SAEED, KAMAL A | 1626 | §112 | Final Rejection | — | Pending | Sep 21, 2022 |
| 17800747 | GLP-1 COMPOSITIONS AND USES THEREOF | ATKINSON, JOSHUA ALEXANDER | 1612 | DP | Final Rejection | 31d overdue | Pending | Aug 18, 2022 |
| 17782313 | FIXED DOSE INJECTION DEVICE | FARRAR, LAUREN PENG | 3783 | §102§103 | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17782003 | AN INJECTION DEVICE FOR DELIVERING A LIQUID DRUG | NORTH, ISABELLA SARAH HYO SO | 3783 | §102§103 | Non-Final OA | — | Pending | Jun 02, 2022 |
| 17638483 | PROCESS FOR PRODUCING A TABLET COMPRISING GLP-1 PEPTIDES | HELLMAN, KRISTINA M | 1654 | §102§112Other | Final Rejection | — | Pending | Feb 25, 2022 |
| 17616283 | APPLICATION OF ANTIARRHYTHMIC AGENTS TO STEM CELL DERIVED CARDIOMYOCYTES AND USES THEREOF | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | — | Pending | Dec 03, 2021 |
| 17614077 | DUAL CHAMBER DRUG RESERVOIR AND STOPPER THEREFOR | RITCHIE, HADEN MATTHEW | 3783 | §102§103 | Final Rejection | — | Pending | Nov 24, 2021 |
| 17403357 | COMPOSITIONS COMPRISING A DELIVERY AGENT AND PREPARATION THEREOF | REYNOLDS, FRED H | 1658 | §103§112Other | Non-Final OA | — | Pending | Aug 16, 2021 |
| 17286639 | ZERO-POINT ADJUSTMENT OF PREFILLED DRUG DELIVERY DEVICE | ZAMORY, JUSTIN L | 3783 | §103 | Final Rejection | — | Pending | Apr 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNovo Nordisk A/S has 28 pending office actions as of October 2026, spread across 10 art units and 23 examiners.
Gyan Chandra has the most, with 3 of Novo Nordisk A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
